IRIS
LEONETTI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.296
AS - Asia 3.116
EU - Europa 1.961
SA - Sud America 482
AF - Africa 193
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.057
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.216
SG - Singapore 1.207
CN - Cina 616
IT - Italia 601
VN - Vietnam 577
BR - Brasile 354
IE - Irlanda 267
HK - Hong Kong 261
SE - Svezia 243
DE - Germania 179
FR - Francia 149
ZA - Sudafrica 123
NL - Olanda 114
IN - India 101
GB - Regno Unito 78
RU - Federazione Russa 72
FI - Finlandia 54
BD - Bangladesh 49
AR - Argentina 48
AT - Austria 43
ID - Indonesia 42
CA - Canada 39
JP - Giappone 35
TR - Turchia 30
IQ - Iraq 29
PH - Filippine 28
KR - Corea 25
ES - Italia 23
MX - Messico 20
PK - Pakistan 20
PL - Polonia 19
CI - Costa d'Avorio 18
CO - Colombia 18
CZ - Repubblica Ceca 18
IR - Iran 18
VE - Venezuela 16
BE - Belgio 15
UA - Ucraina 15
CL - Cile 14
UZ - Uzbekistan 14
EC - Ecuador 13
MA - Marocco 13
TH - Thailandia 13
LT - Lituania 11
SA - Arabia Saudita 11
EG - Egitto 9
GR - Grecia 9
TN - Tunisia 9
BG - Bulgaria 7
MY - Malesia 7
PY - Paraguay 7
TW - Taiwan 7
AU - Australia 6
CH - Svizzera 6
DO - Repubblica Dominicana 6
LU - Lussemburgo 6
AE - Emirati Arabi Uniti 5
CR - Costa Rica 5
PE - Perù 5
BY - Bielorussia 4
JO - Giordania 4
KE - Kenya 4
MD - Moldavia 4
SN - Senegal 4
AZ - Azerbaigian 3
BO - Bolivia 3
ET - Etiopia 3
HR - Croazia 3
HU - Ungheria 3
KZ - Kazakistan 3
NO - Norvegia 3
OM - Oman 3
DK - Danimarca 2
GY - Guiana 2
JM - Giamaica 2
LV - Lettonia 2
PR - Porto Rico 2
PT - Portogallo 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BS - Bahamas 1
BW - Botswana 1
CG - Congo 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
GT - Guatemala 1
KG - Kirghizistan 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
LR - Liberia 1
LY - Libia 1
MK - Macedonia 1
NG - Nigeria 1
Totale 9.044
Salva come PNG Salva come JPEG
Città #
Singapore 689
Ashburn 527
Dallas 418
San Jose 369
Chandler 284
Dublin 262
Hong Kong 243
Santa Clara 183
Ho Chi Minh City 177
Parma 131
Boardman 127
New York 124
Beijing 123
Hanoi 122
Johannesburg 116
Los Angeles 101
Shanghai 90
Munich 84
Lauterbourg 76
Milan 64
Hefei 63
Bologna 55
Council Bluffs 46
Chicago 45
Princeton 38
São Paulo 38
Buffalo 34
Vienna 33
Frankfurt am Main 28
Jakarta 28
Haiphong 26
Helsinki 26
Marseille 26
Moscow 25
Tokyo 25
Ann Arbor 24
Nuremberg 24
Rome 24
Verona 24
Amsterdam 23
Da Nang 23
Turku 23
Atlanta 22
London 22
Des Moines 21
The Dalles 21
Columbus 20
Abidjan 18
Seoul 18
Biên Hòa 17
Chennai 17
Denver 17
Bremen 16
Modena 14
Warsaw 14
Istanbul 13
Orem 13
Reggio Emilia 13
Toronto 13
Montreal 12
Rio de Janeiro 12
West Jordan 12
Belo Horizonte 11
Bengaluru 11
Florence 11
Pune 11
Tashkent 11
Baghdad 10
Brno 10
Brooklyn 10
Fremont 10
Manchester 10
Poplar 10
Redondo Beach 10
Trento 10
Athens 9
Brasília 9
Brussels 9
Chongqing 9
Houston 9
Hải Dương 9
Lahore 9
Seattle 9
Sorbolo 9
Tehran 9
Wilmington 9
Düsseldorf 8
Bangkok 7
Cairo 7
Campinas 7
Curitiba 7
Manaus 7
Manila 7
Phoenix 7
Stockholm 7
Tianjin 7
Boston 6
Brescia 6
Buenos Aires 6
Caracas 6
Totale 5.665
Salva come PNG Salva come JPEG
Nome #
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 243
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 217
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 216
227P Sexual dimorphism in immune profile of early and advanced NSCLC 201
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 201
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 197
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 178
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 175
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 173
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 169
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 169
SARS-CoV-2 Infection Risk and COVID-19 Prevalence and Mortality in Cancer Patients During the First Wave of COVID-19 Pandemic in a Virus Epicenter in Northern Italy 167
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 165
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 165
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 157
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 155
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 145
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 143
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 140
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 137
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 135
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients? 133
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 131
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 131
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial 129
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study 128
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 125
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 125
Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer? 123
Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights 122
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 119
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 118
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 117
Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib 113
Small cell lung cancer: Novel treatments beyond immunotherapy 111
Potential ROle of hypovitaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): a prospective observational study. 111
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 110
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 108
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 106
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 106
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC? 105
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study 105
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study 101
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 100
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy 99
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M? 98
COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors 94
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 94
Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy 94
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 94
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review 92
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 91
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 91
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 91
Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: A retrospective case series 91
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 89
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 89
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 89
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 89
BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature 88
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 84
Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib 81
Can we optimize the selection of patients with lung cancer suitable for EGFR+MET double inhibition? 80
Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) 79
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer 78
Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression 76
“Finding NEMO” in NRAS-mutant melanoma: a step towards a sequential strategy? 75
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy 74
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma 74
Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis 71
The role of the microbiome in cancer and therapy efficacy: Focus on lung cancer 69
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer 67
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 66
Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results 65
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? 60
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study 56
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 52
The link between calcitriol and anticancer immunotherapy: Vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade 52
Response to the Letter re: Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 48
Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC 44
Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges 26
Totale 9.175
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.089
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.089
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202116 0 0 0 0 0 0 0 0 0 0 2 14
2021/2022276 9 4 33 19 2 6 77 15 4 0 27 80
2022/20231.046 111 126 43 87 112 112 20 57 305 3 48 22
2023/2024754 37 49 34 26 74 128 85 35 53 56 60 117
2024/20252.010 63 125 155 149 163 184 137 93 212 193 163 373
2025/20265.012 429 387 820 459 615 297 480 240 715 446 124 0
Totale 9.175